{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.27","value":"98.84"},{"groupId":"OG001","spread":"15.79","value":"13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Day 1, 5 minutes (min) post dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.59","value":"8.73"},{"groupId":"OG001","spread":"10.91","value":"20.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Day 1, 30 min post dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.31","value":"1.82"},{"groupId":"OG001","spread":"0.56","value":"1.96"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Day 1, 5 hours post dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.15","value":"0.44"},{"groupId":"OG001","spread":"0.09","value":"0.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Day 8 pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.22","value":"0.66"},{"groupId":"OG001","spread":"0.12","value":"0.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Day 15 pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.34","value":"0.83"},{"groupId":"OG001","spread":"0.18","value":"0.66"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Day 22 pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"76.6","value":"114.3"},{"groupId":"OG001","spread":"13.24","value":"10.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Day 22, 5 min post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.3","value":"14.9"},{"groupId":"OG001","spread":"10.1","value":"21.69"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Day 22, 30 min post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.05","value":"2.85"},{"groupId":"OG001","spread":"2.07","value":"4.16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Day 22, 5 hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.15","value":"0.53"},{"groupId":"OG001","spread":"0.14","value":"0.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Cycle 2 Day 1, pre-dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"The pharmacokinetic profile of intravenous and subcutaneous bortezomib administration in combination with lenalidomide and dexamethasone.","dispersionType":"Standard Deviation","groups":[{"description":"Induction (Cycles 1-9): Lenalidomide orally, days 1-21. Bortezomib injection, days 1, 8, 15, 22. Dexamethasone orally, days 1, 2, 8, 9, 15, 16, 22, 23 (for subjects 75 years of age or younger), or Dexamethasone orally days 1, 8, 15, 22 (for subjects greater than 75 years of age)\n\nConsolidation (cycles 10-15): Lenalidomide po daily (1-21). Bortezomib sc on days 1, 15\n\nLenalidomide\n\nBortezomib\n\nDexamethasone","id":"OG000","title":"Intravenous"},{"description":"Induction (Cycles 1-9): Lenalidomide orally, days 1-21. Bortezomib injection, days 1, 8, 15, 22. Dexamethasone orally, days 1, 2, 8, 9, 15, 16, 22, 23 (for subjects 75 years of age or younger), or Dexamethasone orally days 1, 8, 15, 22 (for subjects greater than 75 years of age)\n\nConsolidation (cycles 10-15): Lenalidomide po daily (1-21). Bortezomib sc on days 1, 15\n\nLenalidomide","id":"OG001","title":"Subcutaneous"}],"paramType":"MEAN","populationDescription":"A total of only 10 participants per arm were evaluated for drug plasma concentrations following Bortezomib administration.The number of participants vary by time-point due to missing measurements for the concentrations.","reportingStatus":"POSTED","timeFrame":"Day 1 (5 min, 30min, 5 hours post dose), Days 8, 15, Day 22 (pre dose and 5 min, 30 min, 5 hrs post dose), cycle 2 day 1 pre dose","title":"Mean Plasma Bortezomib Concentration Following Intravenous and and Subcutaneous Injection","type":"SECONDARY","unitOfMeasure":"ng/mL"}